Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 10:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1849–1872 of 16,135 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Skin Disorders Clear all

Conditions: Actinic Keratosis
Interventions: KX2-391 Ointment; Drug
Lead sponsor: Athenex, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Atopic Dermatitis
Interventions: Skin Biopsy, Skin tape stripping, Blood draw; Procedure
Lead sponsor: National Jewish Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Idiopathic Inflammatory Myositis (IIM), DERMATOMYOSITIS OR POLYMYOSITIS
Interventions: ULSC (1.5 x 10^8 cells/dose), Placebo (no cells); Biological
Lead sponsor: Restem, LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Gainesville, Florida • Miami, Florida

Conditions: Breast Cancer
Interventions: YWI, Physical Activity; Behavioral
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years to 46 Years · Female only
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 4
States / cities: Brewer, Maine • Boston, Massachusetts • Lowell, Massachusetts + 1 more

Conditions: Cancer, Lung Cancer, Prostate Cancer, Breast Cancer
Interventions: Methionine-restricted diet; Dietary Supplement
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Ichthyosis, Netherton Syndrome
Interventions: Not listed
Lead sponsor: Northwestern University; Other
Eligibility: 1 Year to 60 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2027
U.S. locations: 4
States / cities: Chicago, Illinois • New York, New York

Conditions: Acne Scars - Mixed Atrophic and Hypertrophic, Hyperpigmentation, Laser-Induced Hyperpigmentation
Interventions: Sciton Halo; Device
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Elmsford, New York

Conditions: Melanoma, Head and Neck Cancer, Non Small Cell Lung Cancer, Urothelial Carcinoma
Interventions: Enoblituzumab Schedule 1, Pembrolizumab, Enoblituzumab Schedule 2, retifanlimab; Biological
Lead sponsor: MacroGenics; Industry
Eligibility: 18 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 20
States / cities: Scottsdale, Arizona • Newark, Delaware • Jacksonville, Florida + 17 more

Conditions: Acute Graft-versus-host Disease, Acute GVHD, Chronic Graft-versus-host Disease, Chronic GVHD
Interventions: Skin punch biopsy, Peripheral blood draw; Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Breast Cancer
Interventions: trastuzumab (Herceptin®); Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Peyronie's Disease
Interventions: Vitamin D2, Vitamin E, Testosterone Pellets; Drug
Lead sponsor: Men's Health Boston; Other
Eligibility: 18 Years to 70 Years · Male only
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Chestnut Hill, Massachusetts

Conditions: MPS VI
Interventions: Not listed
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: Not listed
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Oakland, California

Conditions: Malignant Melanoma
Interventions: MDX-010; Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 4
States / cities: Tucson, Arizona • Los Angeles, California • Charlotte, North Carolina + 1 more

Conditions: Temporal Arteritis
Interventions: Not listed
Lead sponsor: University of Pennsylvania; Other
Eligibility: 50 Years and older
Enrollment: 426 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2019
U.S. locations: 7
States / cities: Boston, Massachusetts • Rochester, Minnesota • Cleveland, Ohio + 3 more

Conditions: Infection, Skin and Subcutaneous Tissue Bacterial Infections, Healthcare-associated Infection, Infection Due to Resistant Bacteria
Interventions: Not listed
Lead sponsor: Connie Price; Other
Eligibility: 18 Years and older
Enrollment: 2,298 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 3
States / cities: Denver, Colorado • Washington D.C., District of Columbia

Conditions: Peripheral Neuropathy, Breast Cancer
Interventions: glutamine, Placebo; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Malignant Melanoma, Squamous Cell Carcinoma of Skin
Interventions: THOR-707, Cemiplimab; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Beverly Hills, California

Conditions: Diabetic Foot, Diabetic Foot Ulcer, Foot Ulcer, Diabetic, Foot Wound
Interventions: Lifestyle-focused Occupational Therapy Intervention, Education; Behavioral · Other
Lead sponsor: University of Southern California; Other
Eligibility: 21 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Downey, California • Los Angeles, California

Conditions: Breast Cancer
Interventions: Trastuzumab deruxtecan (T-DXd), Ado-trastuzumab emtansine (T-DM1); Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 524 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 28
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 22 more

Conditions: Radiation Dermatitis, Breast Cancer
Interventions: Dermaprazole 1%, Dermaprazole 2%; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 100 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Metastatic Solid Cancers, Colorectal Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Gastrointestinal Cancer, Ovarian Cancer, Genitourinary Cancer
Interventions: Aldesleukin, Fludarabine, Cyclophosphamide, KRAS TCR-Transduced PBL, GRT-C903/GRT-R904; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 72 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cutaneous Lupus, Systemic Lupus Erythematosus
Interventions: Tofacitinib; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 18 Years to 45 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 2
States / cities: Cincinnati, Ohio • Cleveland, Ohio

Conditions: Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions: bevacizumab, docetaxel, laboratory biomarker analysis; Biological · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 2
States / cities: Aurora, Colorado • Columbus, Ohio

Conditions: Knee Osteoarthritis
Interventions: Sam Ultrasonic Diathermy Device; Device
Lead sponsor: ZetrOZ, Inc.; Industry
Eligibility: 35 Years to 80 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Dryden, New York

Search by objective public record fields.

Ph 1, Single-Center, Safety, Tolerability & Pharmacokinetic Study of KX2 391 Ointment in Subj. w Actinic Keratosis

Identification of Epidermal Signatures in Patients With Atopic Dermatitis

Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM)

Pilot Study for Young Women's Intervention

Methionine-Restricted Diet to Potentiate The Effects of Radiation Therapy

Defining the Skin and Blood Biomarkers of Ichthyosis

Efficacy and Tolerability of a Hybrid Fractional Laser for the Treatment of Acne Scars in Patients With Skin of Color

Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer

Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease

Use of Trastuzumab to Induce Increased ER Expression in ER-negative/Low, Her-2/Neu Positive Breast Cancer

Testosterone Pellets Plus Vitamin D and E Versus Vitamin D and E Alone for the Treatment of Peyronie's Disease

Observational Study of Patients With Mucopolysaccharidosis (MPS) VI Who Previously Participated in ASB-00-02

Study of MDX-010 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma

Determining Disease Activity Biomarkers in Individuals With Giant Cell Arteritis

Study of Accuracy of New Diagnostic Technology to Determine Guide Rapid Antibiotic Treatment for Serious Infections

Randomized Placebo-Controlled Trial of Glutamine for Breast Cancer Patients With Peripheral Neuropathy

A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)

Evaluating a Lifestyle Intervention to Prevent Recurrence of Diabetic Foot Ulcers

DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

Topical Dermaprazole for Radiation Dermatitis in Breast Cancer Patients (TOPAZ)

Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer

Open-label Study of Tofacitinib for Moderate to Severe Skin Involvement in Young Adults With Lupus

Bevacizumab and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer

Wearable LITUS Device for Osteoarthritis of the Knee: a Randomized Double-Blind Placebo-Controlled Trial